Engineered immune cells take aim at lupus in early trial
NCT ID NCT07328581
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This early-stage trial tests a one-time infusion of specially designed immune cells (CAR T cells) in 20 people with severe lupus that hasn't responded to standard treatments. The cells target two proteins (BCMA and CD19) to help reset the immune system and reduce disease activity. The main goals are to check safety and see if participants can achieve remission without needing ongoing lupus medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.